Pharmacophore mapping of Angiotensin Converting Enzymes (ACEs): Insight to Binding Site of ACE1 and ACE2
Abstract
Angiotensin Converting Enzymes (ACEs) are carboxypeptidase enzymes involved in the renin-angiotensin system (RAS), which catalyze angiotensin I by cleavage of the peptide bond. ACE1 has been known as a target for antihypertensive drugs. Another homolog of ACE1, ACE2 has been popular since 2020 because this enzyme is responsible for the SARS-COV2 infection in the human body. Interestingly, it was found that ACE1 inhibitors did not inhibit ACE2. Hence, this study aims to elucidate the pharmacophore of ACE1 and ACE2 in order to understand the mechanism of these different inhibitions. Pharmacophore mapping was carried out using a pharmacophore query editor in the Molecular Operating Environment (MOE). The 3D structures of both enzymes bound to respective inhibitors were prepared and their pharmacophore features were extracted. Besides that, the similarity of both enzymes was analyzed by comparing their amino acid sequences using Align in Uniprot. In addition to pharmacophore mapping, the surfaces of both binding sites were analyzed to obtain a comprehensive evaluation. Results showed that both ACE1 and ACE2 contain nine and eight pharmacophore features, respectively. The amino acid residues of both enzymes were quite similar, especially in the active site. However, both ACE1 and ACE2 inhibitors showed different interactions even though both were well aligned. It was found because the functional groups of both inhibitors were slightly different as well as the active site size of both enzymes. Thus, this might result in different ability of ACE1 inhibitors to occupy the binding site of ACE2. These findings could provide useful information in the design of new selective ACE1 compounds as well as ACE2 compounds.
Keywords
Full Text:
PDFReferences
Ahmad, H., Khan, H., Haque, S., Ahmad, S., Srivastava, N., & Khan, A. (2023). Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension. Journal of the renin-angiotensin-aldosterone system: JRAAS, 2023, 7890188. https://doi.org/10.1155/2023/7890188
Ahmad, I., Pawara, R., Surana, S., & Patel, H. (2021). The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19. Topics in current chemistry (Cham), 379(6), 40. https://doi.org/10.1007/s41061-021-00353-7
Ãlvarez-Zaballos, S., & MartÃnez-Sellés, M. (2023). Angiotensin-Converting Enzyme and Heart Failure. Frontiers in bioscience (Landmark edition), 28(7), 150. https://doi.org/10.31083/j.fbl2807150
Ames, M. K., Atkins, C. E., & Pitt, B. (2019). The renin-angiotensin-aldosterone system and its suppression. Journal of veterinary internal medicine, 33(2), 363–382. https://doi.org/10.1111/jvim.15454
Boutet, E., Lieberherr, D., Tognolli, M., Schneider, M., Bansal, P., Bridge, A. J., Poux, S., Bougueleret, L., & Xenarios, I. (2016). UniProtKB/Swiss-Prot, the Manually Annotated Section of the UniProt KnowledgeBase: How to Use the Entry View. Methods in molecular biology (Clifton, N.J.), 1374, 23–54. https://doi.org/10.1007/978-1-4939-3167-5_2
Burley, S. K., Berman, H. M., Kleywegt, G. J., Markley, J. L., Nakamura, H., & Velankar, S. (2017). Protein Data Bank (PDB): The Single Global Macromolecular Structure Archive. Methods in molecular biology (Clifton, N.J.), 1607, 627–641. https://doi.org/10.1007/978-1-4939-7000-1_26
Cavasotto, C. N., & Phatak, S. S. (2009). Homology modeling in drug discovery: current trends and applications. Drug discovery today, 14(13-14), 676–683. https://doi.org/10.1016/j.drudis.2009.04.006
Danser, A. H. J., Epstein, M., & Batlle, D. (2020). Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension (Dallas, Tex.: 1979), 75(6), 1382–1385. https://doi.org/10.1161/HYPERTENSIONAHA.120.15082
Dutta K. (2022). Allosteric Site of ACE-2 as a Drug Target for COVID-19. ACS pharmacology & translational science, 5(3), 179–182. https://doi.org/10.1021/acsptsci.2c00003
Güner, O. F., & Bowen, J. P. (2014). Setting the record straight: the origin of the pharmacophore concept. Journal of chemical information and modeling, 54(5), 1269–1283. https://doi.org/10.1021/ci5000533
Kai, H., & Kai, M. (2020). Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertension research: official journal of the Japanese Society of Hypertension, 43(7), 648–654. https://doi.org/10.1038/s41440-020-0455-8
Messerli, F. H., Bangalore, S., Bavishi, C., & Rimoldi, S. F. (2018). Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?.Journal of the American College of Cardiology, 71(13), 1474–1482. https://doi.org/10.1016/j.jacc.2018.01.058
Molecular Operating Environment (MOE), 2022.02 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada.
Natesh, R., Schwager, S. L., Evans, H. R., Sturrock, E. D., & Acharya, K. R. (2004). Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry, 43(27), 8718–8724. https://doi.org/10.1021/bi049480n
Natesh, R., Schwager, S. L., Sturrock, E. D., & Acharya, K. R. (2003). Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature, 421(6922), 551–554. https://doi.org/10.1038/nature01370
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., Xu, Y., Cao, Z., & Gao, Z. (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical care (London, England), 24(1), 422. https://doi.org/10.1186/s13054-020-03120-0
Pagliaro, P., Thairi, C., Alloatti, G., & Penna, C. (2022). Angiotensin-converting enzyme 2: a key enzyme in key organs. Journal of cardiovascular medicine (Hagerstown, Md.), 23(1), 1–11. https://doi.org/10.2459/JCM.0000000000001218
Pearson W. R. (2013). An introduction to sequence similarity ("homology") searching. Current protocols in bioinformatics, Chapter 3, 3.1.1–3.1.8. https://doi.org/10.1002/0471250953.bi0301s42
Schaller D, Å ribar D, Noonan T, (2020) Next generation 3D pharmacophore modeling. WIREs Comput Mol Sci. 2020; 10:e1468. https://doi.org/10.1002/wcms.1468
Seidel, T., Wolber, G., & Murgueitio, M.S. (2018) Applied Chemoinformatics. Weinheim: Wiley VCH.
Towler, P., Staker, B., Prasad, S. G., Menon, S., Tang, J., Parsons, T., Ryan, D., Fisher, M., Williams, D., Dales, N. A., Patane, M. A., & Pantoliano, M. W. (2004). ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. The Journal of biological chemistry, 279(17), 17996–18007. https://doi.org/10.1074/jbc.M311191200
Vuorinen, A., & Schuster, D. (2015). Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. Methods (San Diego, Calif.), 71, 113–134. https://doi.org/10.1016/j.ymeth.2014.10.013
DOI: https://doi.org/10.14421/biomedich.2024.132.337-341
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Navista Sri Octa Ujiantari, Cintya Nurul Apsari
Biology, Medicine, & Natural Product Chemistry |